However, before in vitro application, we ensured that the primary concerns associated with employing a new compound, namely target-selectivity and possible toxicity to non-tumor tissues, were not significant factors in our assays: YHO-1701 effectively inhibited the binding of phospho-Tyr peptide to the SH2 domain of STAT3 in a concentration-dependent manner with IC50 values of 2.5 μM for STAT3 and >30 μM for other adapter proteins containing SH2 domains, such as STAT1 and Grb2, thereby demonstrating high selectivity for STAT3 (Fig. 3b and Supplementary Fig. 5a). This evidence concerns the gene STAT1 and neoplasm.